Sanofi is a French multinational pharmaceutical company with significant investments in neurodegenerative disease research. Through its neurology therapeutic area, Sanofi has pursued multiple approaches to treating Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company combines internal R&D capabilities with strategic partnerships to advance its neuroscience pipeline.
| Compound | Mechanism | Phase | Status |
|---|---|---|---|
| Aducanumab collaboration | Anti-amyloid antibody | Commercial | Partner: Biogen |
Sanofi had a collaboration agreement with Biogen for aducanumab development outside the United States, though the company has since shifted focus toward alternative mechanisms.
Sanofi is exploring tau-targeting approaches for Alzheimer's disease and other tauopathies. These programs focus on:
Sanofi's neuroinflammation research targets:
| Compound | Mechanism | Status |
|---|---|---|
| Verubecestat collaboration | BACE inhibitor | Discontinued (2018) |
| Lanabecestat collaboration | BACE inhibitor | Discontinued (2018) |
The BACE inhibitor programs were terminated following negative clinical trial results across the industry, leading Sanofi to pivot toward alternative therapeutic approaches.
| Compound | Mechanism | Phase | Status |
|---|---|---|---|
| Sarizotan | 5-HT1A agonist | Discontinued | - |
| Gene therapy programs | AAV-based delivery | Preclinical | Research |
Sanofi has explored multiple mechanisms for Parkinson's disease, including serotonin receptor modulation and gene therapy approaches for neuroprotection.
Sanofi's multiple sclerosis franchise represents a significant portion of its neuroscience business:
| Product | Mechanism | Status |
|---|---|---|
| Aubagio (teriflunomide) | Dihydroorotate dehydrogenase inhibitor | Commercial |
| Lemtrada (alemtuzumab) | Anti-CD52 antibody | Commercial |
| Mavenclad (cladribine) | Purine analog | Commercial |
Sanofi leverages its global antibody engineering capabilities for CNS applications:
Through its rare disease and neuroscience programs, Sanofi has developed gene therapy capabilities applicable to neurodegeneration:
Sanofi maintains robust small molecule capabilities:
Sanofi and Biogen have collaborated on Alzheimer's disease programs, including commercial agreements for amyloid-targeting antibodies.
Sanofi partners with leading neuroscience research institutions:
The company maintains active partnerships with biotechnology companies for:
Sanofi's neurodegeneration programs have contributed to the field:
Sanofi differentiates itself through: